V. Passos

发表

Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.

Edward S. Kim, M. Tsuboi, T. Mok, 2021, Future oncology.

Effect of verapamil on the pharmacokinetics of pasireotide in healthy volunteers

A. P. Tripathi, V. Passos, K. Hu, 2014, Journal of clinical pharmacology.

Genes Differentially Expressed in Prolactinomas Responsive and Resistant to Dopamine Agonists

D. Giannella‐Neto, M. Bronstein, V. Passos, 2008, Neuroendocrinology.

Prolactinomas resistentes a agonistas dopaminérgicos: diagnóstico e manejo

V. Passos, N. Musolino, 2005 .

Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.

C. Barrios, P. Hoff, V. Passos, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil.

J. Valentim, V. Passos, F. Mataveli, 2008, Arquivos brasileiros de endocrinologia e metabologia.

Pasireotide in dumping syndrome-results from a phase 2, international, multicentre study

J. Tack, J. Aberle, A. P. Beek, 2015 .

ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Jeffrey W. Scott, Keunchil Park, Dong-Wan Kim, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.

C. Barrios, P. Hoff, V. Passos, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.

M. Bronstein, V. Passos, N. Musolino, 2002, The Journal of clinical endocrinology and metabolism.

Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer.

G. Scagliotti, A. Shaw, Keunchil Park, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes

D. Giannella‐Neto, D. Becu-Villalobos, M. Bronstein, 2007, Molecular Cancer.

Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.

Ying Cheng, C. Bai, Yi-long Wu, 2020, Lung cancer.

Safety and efficacy of pasireotide in dumping syndrome—results from a phase 2, multicentre study

S. Bhoyrul, A. V. van Beek, M. Laville, 2018, Alimentary pharmacology & therapeutics.

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous

Keunchil Park, R. Dziadziuszko, Dong-Wan Kim, 2017 .

Metformin-based oral antidiabetic therapy proved effective in hyperglycaemia associated with pasireotide in patients with acromegaly

M. Fleseriu, M. Gadelha, A. Colao, 2015 .

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

P. Postmus, Keunchil Park, R. Dziadziuszko, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3).

G. Scagliotti, A. Shaw, E. Felip, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of octreotide LAR on quality of life of 93 Hungarian patients with neuroendocrine tumors.

V. Passos, T. Gyökeres, P. Kelemen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

J. Blay, P. Wen, Y. Bang, 2023, Nature Medicine.

Analysis of Glucose Profiles in Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia (CML) Patients (pts) Treated with Nilotinib: Lack of Correlation between Glucose Levels and Nilotinib Efficacy.

M. Baccarani, H. Kantarjian, G. Martinelli, 2007 .

OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC

P. Postmus, Keunchil Park, R. Dziadziuszko, 2017 .

Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)

G. Scagliotti, A. Shaw, T. Mok, 2016 .

Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

V. Passos, Yvonne Y. Lau, Ying Hong, 2017, Journal of clinical pharmacology.

Journal Pre-proof Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALK i-Naïve Patients With ALK -Rearranged Non–Small-Cell Lung Cancer Phase II Study of in i-Naïve Patients With ALK -Rearranged Non–Small-Cell

A. Shaw, E. Felip, D. Spigel, 2019 .

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

E. Felip, R. Caparica, M. Garassino, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.